Furumai R - Search Results

1

Perturbation of ribosome biogenesis drives cells into senescence through 5S RNP-mediated p53 activation.

Nishimura K, Kumazawa T, Kuroda T, Katagiri N, Tsuchiya M, Goto N, Furumai R, Murayama A, Yanagisawa J, Kimura K. Nishimura K, et al. Among authors: furumai r. Cell Rep. 2015 Mar 3;10(8):1310-23. doi: 10.1016/j.celrep.2015.01.055. Epub 2015 Feb 26. Cell Rep. 2015. PMID: 25732822 Free article.

2

CHIP buffers heterogeneous Bcl-2 expression levels to prevent augmentation of anticancer drug-resistant cell population.

Tsuchiya M, Nakajima Y, Waku T, Hiyoshi H, Morishita T, Furumai R, Hayashi Y, Kishimoto H, Kimura K, Yanagisawa J. Tsuchiya M, et al. Among authors: furumai r. Oncogene. 2015 Aug 27;34(35):4656-63. doi: 10.1038/onc.2014.387. Epub 2014 Dec 1. Oncogene. 2015. PMID: 25435366

3

The E3 ubiquitin ligase activity of Trip12 is essential for mouse embryogenesis.

Kajiro M, Tsuchiya M, Kawabe Y, Furumai R, Iwasaki N, Hayashi Y, Katano M, Nakajima Y, Goto N, Watanabe T, Murayama A, Oishi H, Ema M, Takahashi S, Kishimoto H, Yanagisawa J. Kajiro M, et al. Among authors: furumai r. PLoS One. 2011;6(10):e25871. doi: 10.1371/journal.pone.0025871. Epub 2011 Oct 18. PLoS One. 2011. PMID: 22028794 Free PMC article.

4

The role of class I histone deacetylase (HDAC) on gluconeogenesis in liver.

Oiso H, Furukawa N, Suefuji M, Shimoda S, Ito A, Furumai R, Nakagawa J, Yoshida M, Nishino N, Araki E. Oiso H, et al. Among authors: furumai r. Biochem Biophys Res Commun. 2011 Jan 7;404(1):166-72. doi: 10.1016/j.bbrc.2010.11.086. Epub 2010 Nov 23. Biochem Biophys Res Commun. 2011. PMID: 21108932

5

UBE3A regulates the transcription of IRF, an antiviral immunity.

Furumai R, Tamada K, Liu X, Takumi T. Furumai R, et al. Hum Mol Genet. 2019 Jun 15;28(12):1947-1958. doi: 10.1093/hmg/ddz019. Hum Mol Genet. 2019. PMID: 30690483 Free PMC article.

6

FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.

Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S. Furumai R, et al. Cancer Res. 2002 Sep 1;62(17):4916-21. Cancer Res. 2002. PMID: 12208741

7

Histone deacetylase inhibitors block nuclear factor-κB-dependent transcription by interfering with RNA polymerase II recruitment.

Furumai R, Ito A, Ogawa K, Maeda S, Saito A, Nishino N, Horinouchi S, Yoshida M. Furumai R, et al. Cancer Sci. 2011 May;102(5):1081-7. doi: 10.1111/j.1349-7006.2011.01904.x. Epub 2011 Mar 4. Cancer Sci. 2011. PMID: 21299717 Free article.

8

Histone deacetylase as a new target for cancer chemotherapy.

Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S. Yoshida M, et al. Among authors: furumai r. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S20-6. doi: 10.1007/s002800100300. Cancer Chemother Pharmacol. 2001. PMID: 11587361 Review.

9

Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin.

Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. Furumai R, et al. Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):87-92. doi: 10.1073/pnas.98.1.87. Proc Natl Acad Sci U S A. 2001. PMID: 11134513 Free PMC article.

10

Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.

Komatsu Y, Tomizaki KY, Tsukamoto M, Kato T, Nishino N, Sato S, Yamori T, Tsuruo T, Furumai R, Yoshida M, Horinouchi S, Hayashi H. Komatsu Y, et al. Among authors: furumai r. Cancer Res. 2001 Jun 1;61(11):4459-66. Cancer Res. 2001. PMID: 11389076

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16 results

Search Page